Delving into the Latest Updates on Iltamiocel (Cook MyoSite) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

AMDC - Cook MyoSite, AMDC-USR, Autologous muscle derived cells - Cook MyoSite

+ [1]

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Digestive System DisordersUrogenital DiseasesNeoplasms+ [3]

Active Indication

Fecal IncontinenceUrinary Incontinence, StressDeglutition Disorders+ [1]

Inactive Indication-

Originator Organization

Cook MyoSite, Inc.

Active Organization

Cook MyoSite, Inc.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a confirmatory/bridging study to evaluate the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) compared with placebo in the treatment of stress urinary incontinence (SUI) in adult Japanese female subjects. Half of the participants will receive AMDC-USR (injections with cells) and the other half will receive placebo.

Start Date01 Jun 2025

Sponsor / Collaborator

Cook MyoSite, Inc.

NCT06743620

/ Not yet recruitingNot Applicable

Prospective Observational Long-Term Safety and Effectiveness Registry of Patients Who Have Received Iltamiocel as Part of Cook Myosite, Inc. Sponsored CELLEBRATE Clinical Study in Patients With Persistent or Recurrent Stress Urinary Incontinence (SUI) Following Surgical Treatment

The main purpose of this registry is to collect observational, long-term safety and effectiveness data in subjects who have received at least one dose of iltamiocel as part of the CLBT clinical study.

Start Date01 Mar 2025

Sponsor / Collaborator

Cook MyoSite, Inc.

NCT05776277

/ RecruitingPhase 3

A Two-stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel With Placebo in the Treatment of Female Participants With Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)

This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.

Start Date21 Mar 2024

Sponsor / Collaborator

Cook MyoSite, Inc.

100 Clinical Results associated with Iltamiocel (Cook MyoSite)

Login to view more data

100 Translational Medicine associated with Iltamiocel (Cook MyoSite)

Login to view more data

100 Patents (Medical) associated with Iltamiocel (Cook MyoSite)

Login to view more data

15

Literatures (Medical) associated with Iltamiocel (Cook MyoSite)

01 Nov 2024·Neurourology and Urodynamics

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double‐Blind, Randomized, Stratified, Placebo‐Controlled Trial

Article

Author: Antosh, Danielle ; Peters, Kenneth M. ; Marguet, Charles G. ; Lee, Una J. ; Tarnay, Christopher M. ; Kaufman, Melissa R. ; Snyder, Scott ; Heit, Michael H. ; Goldman, Howard B. ; Dmochowski, Roger ; Benson, Kevin D. ; Rehme, Christian ; Sokol, Eric R. ; Kennelly, Michael J. ; Canestrari, Emanuele ; Quiroz, Lieschen H. ; Chancellor, Michael B. ; Wolter, Christopher E. ; Jankowski, Ron J. ; Karram, Mickey ; Bennett, Jason B. ; Chermansky, Christopher J. ; Katz, Daniel M. ; Thomas, Sherry

ABSTRACTAimsThis study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI).MethodsAdult females were randomized 2:1 to iltamiocel (150 × 106 cells) or placebo and stratified by severity and prior SUI surgery. The primary objective was efficacy based on the frequency of stress incontinence episodes (SIE) recorded in a 3‐day diary at 12 months posttreatment. After 12 months, placebo participants could elect to receive open‐label iltamiocel. Efficacy and safety analyses were performed using all patients as treated populations.ResultsThe study enrolled 311 patients, 297 were randomized to either iltamiocel (n = 199) or placebo (n = 98). Of the 295 participants that completed 12 months blinded follow‐up, the proportion achieving the primary endpoint of ≥ 50% SIE reduction was not statistically different between treatment groups (52% vs. 53.6%; p = 0.798). A significantly greater proportion of iltamiocel participants in the prior SUI surgery stratum group achieved ≥ 75% SIE reduction compared with placebo, (40% vs. 16%; p = 0.037). Treatment response was maintained at 24 months in 78.4% and 64.9% of iltamiocel participants who achieved ≥ 50% and ≥ 75% SIE reduction, respectively, at Month 12. Adverse events related to the treatment were reported in 19 (9.5%) iltamiocel participants and 6 (6.1%) placebo participants.ConclusionThe study did not meet its primary endpoint however, iltamiocel cell therapy is safe and may be ideally suited to female patients who have undergone prior surgery for SUI. Additional study in this group of patients with high unmet medical needs is warranted.Trial RegistrationClinicalTrials.gov identifier: NCT01893138; EudraCT number: 2014‐002919‐41.

01 Feb 2024·Protein Expression and Purification

Antibody-mimetic drug conjugate with efficient internalization activity using anti-HER2 VHH and duocarmycin

Article

Author: Chansler, Michael ; Kawamura, Takeshi ; Sakata, Juri ; Ishii, Masazumi ; Tatsumi, Toshifumi ; Miura, Mai ; Takahashi, Kazuki ; Inagaki, Yuya ; Tanaka, Toshiya ; Kanai, Motomu ; Yamashita, Takefumi ; Osawa, Tsuyoshi ; Katoh, Hiroto ; Aki, Sho ; Yamatsugu, Kenzo ; Sugiyama, Akira ; Ishikawa, Shumpei ; Tsukagoshi, Masanobu ; Kaneko, Yudai ; Tokuyama, Hidetoshi ; Kodama, Tatsuhiko ; Shimizu, Akihiro

Antibody-mimetic drug conjugate (AMDC) is a cancer cell-targeted drug delivery system based on the non-covalent binding of mutated streptavidin and modified biotin, namely Cupid and Psyche. However, the development of AMDCs is hampered by difficulties in post-translational modification or poor internalization activity. Here, we report an expression, refolding, and purification method for AMDC using a variable heavy chain of heavy chain-only antibodies (VHHs). Monomeric anti-HER2 VHH fused to Cupid was expressed in Escherichia coli inclusion bodies. Solubilization and refolding at optimized reducing conditions and pH levels were selected to form a functional, tetrameric protein (anti-HER2 VHH-Cupid) that can be easily purified based on molecular weight. Anti-HER2 VHH-Cupid non-covalently creates a tight complex with Psyche linked to a potent DNA-alkylating agent, duocarmycin. This complex can be absorbed by the HER2-expressing human breast cancer cell line, KPL-4, and kills KPL-4 cells in vitro and in vivo. The production of a targeting protein with internalizing activity, combined with the non-covalent conjugation of a highly potent payload, renders AMDC a promising platform for developing cancer-targeted therapy.

01 Apr 2022·Protein Expression and PurificationQ4 · BIOLOGY

Antibody mimetic drug conjugate manufactured by high-yield Escherichia coli expression and non-covalent binding system

Q4 · BIOLOGY

Article

Author: Ishii, Masazumi ; Ishikawa, Shumpei ; Kaneko, Yudai ; Katoh, Hiroto ; Kodama, Tatsuhiko ; Kanai, Motomu ; Kawamura, Takeshi ; Tatsumi, Toshifumi ; Aki, Sho ; Ohkubo, Kei ; Sugiyama, Akira ; Takahashi, Kazuki ; Yamatsugu, Kenzo ; Yamashita, Takefumi ; Miura, Mai ; Osawa, Tsuyoshi

Antibody-drug conjugates (ADCs) are a major therapeutic tool for the treatment of advanced cancer. Malignant cells in advanced cancer often display multiple genetic mutations and become resistant to monotherapy. Therefore, a therapeutic regimen that simultaneously targets multiple molecules with multiple payloads is desirable. However, the development of ADCs is hampered by issues in biopharmaceutical manufacturing and the complexity of the conjugation process of low-molecular-weight payloads to biologicals. Here, we report antibody mimetic-drug conjugates (AMDCs) developed by exploiting the non-covalent binding property of payloads based on high-affinity binding of mutated streptavidin and modified iminobiotin. Miniprotein antibodies were fused to a low immunogenic streptavidin variant, which was then expressed in Escherichia coli inclusion bodies, solubilized, and refolded into functional tetramers. The AMDC developed against human epidermal growth factor receptor 2 (HER2) effectively killed cultured cancer cells using bis-iminobiotin conjugated to photo-activating silicon phthalocyanine. The HER2-targeting AMDC was also effective in vivo against a mouse KPL-4 xenograft model. This AMDC platform provides rapid, stable, and high-yield therapeutics against multiple targets.

100 Deals associated with Iltamiocel (Cook MyoSite)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fecal Incontinence	Phase 3	United States	Cook MyoSite, Inc.	21 Mar 2024
Urinary Incontinence, Stress	Phase 3	United Kingdom	Cook MyoSite, Inc.	04 Nov 2011
Deglutition Disorders	Phase 2	United States	Cook MyoSite, Inc.	26 May 2022
Squamous Cell Carcinoma of the Oropharynx	Phase 2	United States	Cook MyoSite, Inc.	26 May 2022
Urinary Incontinence, Stress	Phase 1	Germany	Cook MyoSite, Inc.	04 Nov 2011
Urinary Incontinence, Stress	Phase 1	Canada	Cook MyoSite, Inc.	04 Nov 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01893138 (Pubmed \| Neurourol Urodyn) Manual	Phase 3	Urinary Incontinence, Stress	297	Iltamiocel (150 × 10^6 cells)	(uairlztyou) = vhjtmojzsd eenbahxrcn (vsgmlciayo ) Not Met View more	Negative	16 Sep 2024
NCT01893138 (Pubmed \| Neurourol Urodyn) Manual	Phase 3	Urinary Incontinence, Stress	297	Placebo	(uairlztyou) = sqzyfmhkbu eenbahxrcn (vsgmlciayo ) Not Met View more	Negative	16 Sep 2024
NCT01600755 (CTgov)	Phase 1/2	Fecal Incontinence	53	Iltamiocel	pszgusdinr(xdckobuwvr) = sacbedklpw tqymkcvjpj (znbbirnlby, nfjbdczqcl - kkoynasrsr) View more	-	16 Feb 2024
NCT01893138 (2014-002919-41 \| ###DELETE, CTgov)	Phase 3	Urinary Incontinence, Stress	311	Iltamiocel (Iltamiocel)	iljawlpgpc(quumlaptez) = elxnkllyzm qgngqunkfr (fimieeuqzi, nklfdqzahu - xibkmipqwl) View more	-	05 Jan 2023
NCT01893138 (2014-002919-41 \| ###DELETE, CTgov)	Phase 3	Urinary Incontinence, Stress	311	Placebo (Placebo)	iljawlpgpc(quumlaptez) = jmvndfqwew qgngqunkfr (fimieeuqzi, blhronmozv - upynyjhabz) View more	-	05 Jan 2023
NCT02291432 (CTgov)	Phase 1/2	Urinary Incontinence, Stress	25	autologous muscle-derived cells (AMDC)	zsncvolyxu(rhtyzwmdml) = bqlghlriko kofyeuzxaw (wswecmcswk, opgxljtcmk - tfvyiygjct) View more	-	26 Oct 2021
NCT01382602 (CTgov)	Phase 3	Urinary Incontinence, Stress	150	AMDC-USR (AMDC-USR)	pqfjalxqwp(ekvcclmhtw) = jxnnwvntex utoujhkmcy (gidvqjjxxd, kaxtfhmonx - jblqphmibw) View more	-	17 May 2018
NCT01382602 (CTgov)	Phase 3	Urinary Incontinence, Stress	150	Placebo (Placebo)	pqfjalxqwp(ekvcclmhtw) = nruplxopvp utoujhkmcy (gidvqjjxxd, vukjnxykco - vhpaoenqod) View more	-	17 May 2018
NCT01008943 (CTgov)	Phase 2	Urinary Incontinence, Stress	16	Autologous Muscle-Derived Cells (AMDC)	gtluzezoft(xzeacntysh) = qipjzdxilh tnkvvazdcl (xhvbrtfwxo, qufpbxttnx - qokqejefqz) View more	-	03 Nov 2015